Literature DB >> 1694972

Characterization of histamine H2-receptors in human neutrophils with a series of guanidine analogues of impromidine. Are cell type-specific H2-receptors involved in the regulation of NADPH oxidase?

R Burde1, A Buschauer, R Seifert.   

Abstract

Human neutrophils possess an NADPH oxidase which catalyzes superoxide (O2-) formation and is activated by chemotactic peptides. Histamine inhibits O2- formation via H2-receptors (Burde et al. 1989). We characterized the neutrophil H2-receptor with a series of new guanidine-type H2-agonists structurally derived from impromidine. Histamine inhibited O2- formation with an IC50 value of 6.7 +/- 1.2 microM. Five aryloxy- and arylthioalkylguanidines were less potent and effective than histamine. Several arpromidine-like phenyl(pyridylalkyl)guanidines were either full or partial H2-agonists. Some guanidines possess a three-membered carbon chain connecting the aromatic rings and the guanidine group; they were similarly potent and effective as histamine. Shortening or elongation of the carbon chain substantially decreased the potency and intrinsic activity of the guanidines. Halogenation of the phenyl ring did not substantially affect the potency and intrinsic activity of the compounds in comparison to the non-substituted parent compound. The H2-antagonist, famotidine, competitively antagonized inhibition of O2- formation caused by the guanidine, arpromidine, with a pA2 value of 6.84. The H2-antagonist, cimetidine, differentially counteracted inhibition caused by partial and full H2-agonists. Partial H2-agonists antagonized the effects of histamine. The inhibitor of phosphodiesterases, 3-isobutyl-1-methylxanthine, additively enhanced the inhibitory effects of histamine and guanidines. The properties of the neutrophil H2-receptor were compared with literature data concerning properties of the H2-receptor of the guinea pig atrium. In the latter system, guanidines are full H2-agonists with potencies of up to 125-fold of that of histamine. Our data indicate that guanidines inhibit O2- formation in human neutrophils via H2-receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1694972     DOI: 10.1007/bf00176340

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  31 in total

Review 1.  What are the differences between the H2-receptor antagonists?

Authors:  W Schunack
Journal:  Aliment Pharmacol Ther       Date:  1987       Impact factor: 8.171

Review 2.  The O2- -forming NADPH oxidase of the phagocytes: nature, mechanisms of activation and function.

Authors:  F Rossi
Journal:  Biochim Biophys Acta       Date:  1986-11-04

3.  [Synthesis of positive intropic substances: aryloxyalkylguanidines].

Authors:  A Buschauer
Journal:  Arch Pharm (Weinheim)       Date:  1988-05       Impact factor: 3.751

4.  The determination of receptor constants for histamine H2-agonists in the guinea-pig isolated right atrium using an irreversible H2-antagonist.

Authors:  T J Rising; A Steward
Journal:  Br J Pharmacol       Date:  1986-01       Impact factor: 8.739

5.  Synthesis and in vitro pharmacology of arpromidine and related phenyl(pyridylalkyl)guanidines, a potential new class of positive inotropic drugs.

Authors:  A Buschauer
Journal:  J Med Chem       Date:  1989-08       Impact factor: 7.446

6.  Activation of NADPH oxidase by purine and pyrimidine nucleotides involves G proteins and is potentiated by chemotactic peptides.

Authors:  R Seifert; R Burde; G Schultz
Journal:  Biochem J       Date:  1989-05-01       Impact factor: 3.857

7.  Purine and pyrimidine nucleotides potentiate activation of NADPH oxidase and degranulation by chemotactic peptides and induce aggregation of human neutrophils via G proteins.

Authors:  R Seifert; K Wenzel; F Eckstein; G Schultz
Journal:  Eur J Biochem       Date:  1989-04-15

8.  Effects of histamine agonists and antagonists on luminol-dependent chemiluminescence of granulocytes.

Authors:  Y Ozaki; S Kume; T Ohashi
Journal:  Agents Actions       Date:  1984-10

9.  Impromidine (SK & F 92676) acts as a partial agonist on the isolated whole stomach of the rat.

Authors:  M Parsons; C Sykes
Journal:  Br J Pharmacol       Date:  1980-05       Impact factor: 8.739

Review 10.  Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides.

Authors:  R Seifert; G Schultz
Journal:  Trends Pharmacol Sci       Date:  1989-09       Impact factor: 14.819

View more
  6 in total

Review 1.  Pharmacological Characterization of Human Histamine Receptors and Histamine Receptor Mutants in the Sf9 Cell Expression System.

Authors:  Erich H Schneider; Roland Seifert
Journal:  Handb Exp Pharmacol       Date:  2017

Review 2.  Molecular and cellular analysis of human histamine receptor subtypes.

Authors:  Roland Seifert; Andrea Strasser; Erich H Schneider; Detlef Neumann; Stefan Dove; Armin Buschauer
Journal:  Trends Pharmacol Sci       Date:  2012-12-17       Impact factor: 14.819

3.  The effect of histamine on the oxidative burst of HL60 cells before and after exposure to reactive oxygen species.

Authors:  T L Ching; J G Koelemij; A Bast
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

4.  Modulation of IgE-mediated histamine release from human leukocytes by a new class of histamine H2-agonists.

Authors:  J Kleine-Tebbe; A Buschauer; A Friese; W Schunack; G Kunkel
Journal:  Agents Actions       Date:  1992-03

5.  Histamine H1-receptors in HL-60 monocytes are coupled to Gi-proteins and pertussis toxin-insensitive G-proteins and mediate activation of Ca2+ influx without concomitant Ca2+ mobilization from intracellular stores.

Authors:  R Seifert; L Grünbaum; G Schultz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-04       Impact factor: 3.000

6.  Cationic-amphiphilic arpromidine-derived guanidines and a histamine trifluoromethyl-toluidide derivative may activate pertussis toxin-sensitive G-proteins by a receptor-independent mechanism.

Authors:  A Hagelüken; R Burde; B Nürnberg; R Harhammer; A Buschauer; R Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-03       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.